Diagnosis and management of infection caused by chlamydia
Patent 6579854 Issued on June 17, 2003. Estimated Expiration Date: 
May 6, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 6, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesReagents and method for therapeutic treatment of multiple sclerosis Antibacterial coated medical implants Method of screening for arterial chlamydial granuloma Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment Clinical uses of polyene macrolides Methods for in vitro susceptibility testing of chlamydia Patent #: 6258532 InventorsAssigneeApplicationNo. 073661 filed on 05/06/1998US Classes:514/31, The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.)514/152, 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI514/192, 1-thia-4-aza-bicyclo (3.2.0) heptane ring containing (including dehydrogenated) (e.g., penicillins, etc.)514/198, Ampicillin per se or salt thereof514/311, Quinolines (including hydrogenated)514/601, Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E)514/631Amidines (i.e., N=C-N)ExaminersPrimary: Weddington, Kevin E.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/70A61K 031/65 A61K 031/43 A61K 031/47 A61K 031/18 AbstractThe present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Other References
Field of SearchPLURAL FERMENTATES OF DIFFERENT ORIGIN (E.G., MIXTURES OF ANTIBIOTICS, ETC.)Chlamydia (e.g., Chlamydia trachomatis, etc.) INVOLVING AN INSOLUBLE CARRIER FOR IMMOBILIZING IMMUNOCHEMICALS Corrosion resistance or power Involving a micro-organism or cell membrane bound antigen or cell membrane bound receptor or cell membrane bound antibody or microbial lysate Binds bacterium or similar microorganism or component or product thereof (e.g., Pseudomonas, Chlamydia, Clostridium, bacterium-associated antigen, etc.) PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES Antibiotics DNA or RNA fragments or modified forms thereof (e.g., genes, etc.) Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNA Probes for detection of microbial nucleotide sequences The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.) Amidines (i.e., N=C-N) 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI 1-thia-4-aza-bicyclo (3.2.0) heptane ring containing (including dehydrogenated) (e.g., penicillins, etc.) Ampicillin per se or salt thereof Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E) Quinolines (including hydrogenated) | |
